A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
Jasper J. Haringman(Isala), Paul P. Tak(Amsterdam UMC Location University of Amsterdam), Barry Bresnihan(St. Vincent's University Hospital), Filip Van den Bosch(Ghent University Hospital), Dominique Baeten(University of Amsterdam), Tom Smeets(Tilburg University), Hermann Gram(Novartis (Switzerland)), François Legay(Inserm), Pius Loetscher(Novartis (Switzerland)), Thasia Woodworth(Novartis (Switzerland)), Robert Schmouder(Novartis (Switzerland)), Huib J. Dinant(Amsterdam UMC Location University of Amsterdam), Ferdinand C. Breedveld(Leiden University Medical Center), Daniëlle M. Gerlag(UCB Pharma (United Kingdom))
Cited by 255
Related Papers
NF-κB: a key role in inflammatory diseases
|Journal of Clinical Investigation|2001|3.9k
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
Common variants at CD40 and other loci confer risk of rheumatoid arthritis
|Nature Genetics|2008|542
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2004|464